Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Pharma Two B","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Myung in Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Myung In Pharm

    Menu

    Myung In Pharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Myung In Pharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Myung in Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

              Details:

              The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for the treatment of mild to moderate dementia associated with Alzheimer's disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivalif

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Luye Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Myung In Pharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea

              Details:

              Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.

              Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate

              Therapeutic Area: Neurology Product Name: P2B001

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Pharma Two B

              Deal Size: $5.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY